dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics)

N/A

Report date: 2022/01/17 12:14:22

Base Information

Drug NamedPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics)

Drug Alias Namearmored dnPD-1 +CD19CARdPD-1 hCD19 CART细胞疗法（上海斯丹赛生物技术）PD-1 CD19CARTdnPD1-CAR19dnPD1 armored anti-CD19 CAR-T Cell +[10]

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsProgrammed cell death protein 1 modulators

TargetsB-lymphocyte antigen CD19Programmed cell death protein 1

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesInnovative Cellular Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesInnovative Cellular Therapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A